The authors reviewed two decades of psychiatric genomics and identified specific decision points where a genetic result changes what a clinician does next. Used at the right moment for the right person, testing can shorten a diagnosis, guide a prescription, and flag physical health risks early.
Genes Can Guide Which Medication Comes First
The most immediate application is pharmacogenetics, which examines how a person’s genes affect the way their body processes a medication. Psychiatric prescribing often runs on trial and error, a pattern the JAMA Psychiatry authors link to high rates of treatment discontinuation and suboptimal outcomes.
Variation in drug-metabolizing enzymes including CYP2D6 and CYP2C19 can change the amount of a drug circulating in the blood by several-fold. Two people on an identical dose can end up with very different exposure.
In major depressive disorder, the authors cite meta-analytic evidence putting the odds ratio for remission at roughly 1.4 when prescribing is guided by pharmacogenomic results rather than treatment as usual, a modest but clinically relevant benefit.
Some genetic testing is already standard care. Human leukocyte antigen genotyping before carbamazepine is prescribed screens for risk of a severe drug reaction, a case where one result prevents serious harm.
Testing Can End a Years-Long Diagnostic Search
Rare variants with large effects turn up often enough to be worth looking for in the right populations. The paper reports they have been identified in 13% of people with ADHD, 14% of those with autism spectrum disorder, 6% of those with schizophrenia, and 30% to 50% of those with intellectual disability.
Finding one can do a great deal at once. According to the authors, a molecular diagnosis can end a diagnostic odyssey, sharpen family recurrence risk estimates, inform prognosis, trigger syndrome-specific physical health screening, guide medication choice, open access to family or government support, and make someone eligible for clinical trials.
It can also reduce stigma and improve adherence by changing how a person and their family understand what they are dealing with.
The delays this could shorten average more than seven years for rare neuropsychiatric genetic conditions. Access is the bottleneck rather than the science.
In the SPARK autism study of 21,532 participants, only 6.8% reported chromosomal microarray testing and 1% whole-exome sequencing.
Risk Estimates Get Sharper in High-Risk Groups
Polygenic scores summarize the combined effect of many common genetic variants, and how useful they are depends heavily on who is tested.
Inside groups already at elevated risk, the numbers become useful for decisions. Among people at clinical high risk for psychosis, where roughly 25% develop schizophrenia against a general population prevalence near 1%, the authors describe stratification running from 5% to 10% risk in the lowest decile up to 50% to 60% in the highest.
Children of people with severe psychiatric disorders are another such group. Around 55% will develop a psychiatric disorder themselves, and the authors suggest testing may refine individual risk beyond family history alone. It can also offer reassurance when risk turns out lower than a family feared.
Treatment Resistance Is Itself a Signal Worth Testing
When someone has not responded to repeated treatment attempts, genetics may help explain why. The paper cites a study in which up to 48.2% of people with severe, extremely treatment-resistant schizophrenia carried damaging missense or loss-of-function variants in genes tied to the condition.
Rare copy number variants have also been linked to poorer response to antipsychotic medication. Testing at that stage cannot undo the difficult years, but it can redirect a plan that has stalled.
Genetics Can Protect Physical Health Too
One opportunity the paper raises has little to do with psychiatric symptoms. People with psychiatric disorders have substantially reduced life expectancy, driven largely by higher rates of physical illness.
Polygenic scores for conditions such as cardiovascular disease or obesity may help identify who carries elevated risk, supporting earlier integrated care.
Where the Evidence Stops Short
The authors are specific about the boundaries, and those boundaries are what make the targeted uses credible. Population-wide screening is not supported.
Delivery matters as much as the result. The authors point to genetic counseling built around what a person can influence, including treatment adherence and avoiding known risk factors such as cannabis use.
Counseling of that kind has been associated with greater patient empowerment, less internalized stigma, and fewer psychiatric symptoms over time.
What This Means for Mental Health Treatment Seekers
Genetic testing is worth asking about in specific terms rather than as a general service. Pharmacogenomic testing can inform which medication a prescriber tries first and at what dose.
Rare-variant testing has clear value when intellectual disability, very early onset, cognitive impairment, or treatment resistance is in the picture.
Ask whether results arrive with counseling attached, because the JAMA Psychiatry authors treat that as the difference between clarity and distress.
Finding the Right Rehab
A few questions sharpen the comparison between programs treating mental health conditions alongside substance use. Ask whether care for co-occurring conditions is integrated rather than sequential.
Ask how medication management works and whether pharmacogenomic results would inform prescribing. Ask whether the program screens for physical health conditions, since that is where the life expectancy gap is created. Verify credentials and accreditation, and confirm insurance coverage before admission.
Rehab.com’s directory lets you compare verified treatment centers by location, level of care, and insurance accepted before you call. You can also call
800-985-8516
( 
Sponsored Helpline )
to get more information about which treatment options are best for your needs.
